Atholl Johnston, Roland Asmar, Björn Dahlöf, Kate Hill, David Albert Jones, Jens Jordan, Michael Livingston, Graham MacGregor, Michael Sobanja, Panagiotis Stafylas,Enrico Agabiti Rosei & José Zamorano. Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe. British Journal of Clinical Pharmacology 2011; 72:5 / 727–730
Poquette MA, Lensmeyer GL, Doran TC. Effective Use of Liquid Chromatography-Mass Spectrometry (LC/MS) in the Routine Clinical Laboratory for Monitoring Sirolimus, Tacrolimus, and Cyclosporine. Ther.Drug Monit. 2005;27(2):144-50.
Poquette MA, Lensmeyer GL, Doran TC. Effective Use of Liquid Chromatography-Mass Spectrometry (LC/MS) in the Routine Clinical Laboratory for Monitoring Sirolimus, Tacrolimus, and Cyclosporine. Ther.Drug Monit. 2005;27(2):144-50.
Koefoed-Nielsen PB, Karamperis N, Jorgensen KA. Validation of the calcineurin phosphatase assay. Clin Chem. 2004;50(12):2331-7.
· Wallemacq PE. Therapeutic monitoring of immunosuppressant drugs. Where are we? Clin Chem.Lab Med. 2004;42(11):1204-11.
Anglicheau D, Legendre C, Thervet E. Pharmacogenetics in solid organ transplantation: present knowledge and future perspectives. Transplantation 2004;78(3):311-5.
Taylor PJ. Therapeutic drug monitoring of immunosuppressant drugs by high-performance liquid chromatography-mass spectrometry. Ther.Drug Monit. 2004;26(2):215-9.
Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem YF. Alterations of CYP3A4 and P-glycoprotein activity in vivo with time in renal graft recipients. Kidney Int. 2004;66(1):433-40.
Morris RG, Holt DW, Armstrong VW, Griesmacher A, Napoli KL, Shaw LM. Analytic aspects of cyclosporine monitoring, on behalf of the IFCC/IATDMCT joint working group. Therapeutic Drug Monitoring 2004;26:227-30.
Holt DW, Johnston A. Monitoring immunosuppressive drugs: Has it a future? Therapeutic Drug Monitoring 2004;26:244-7.
Butler JA, Peveler RC, Roderick P, Horne R, Mason JC. Measuring compliance with drug regimens after renal transplantation: comparison of self-report and clinician rating with electronic monitoring. Transplantation 2004;77(5):786-9.
Jorga A, Holt DW, Johnston A. Therapeutic drug monitoring of cyclosporine. Transplant.Proc. 2004;36(2 Suppl):396S-403S.
Citterio F. Evolution of the therapeutic drug monitoring of cyclosporine. Transplant.Proc. 2004;36(2 Suppl):420S-5S.
Brunet M, Millan O, Jimenez O, Campistol JM, Vidal E, Rojo I et al. New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations. Transplant.Proc. 2004;36(2 Suppl):437S-41S.
Perico N, Ruggenenti P, Gotti E, Gaspari F, Cattaneo D, Valente U et al. In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: Insights from the MY.S.S. Trial. Kidney Int. 2004;65(3):1084-90.
Poquette MA, Lensmeyer GL, Doran TC. Effective Use of Liquid Chromatography-Mass Spectrometry (LC/MS) in the Routine Clinical Laboratory for Monitoring Sirolimus, Tacrolimus, and Cyclosporine. Ther.Drug Monit. 2005;27(2):144-50.
Poquette MA, Lensmeyer GL, Doran TC. Effective Use of Liquid Chromatography-Mass Spectrometry (LC/MS) in the Routine Clinical Laboratory for Monitoring Sirolimus, Tacrolimus, and Cyclosporine. Ther.Drug Monit. 2005;27(2):144-50.
Koefoed-Nielsen PB, Karamperis N, Jorgensen KA. Validation of the calcineurin phosphatase assay. Clin Chem. 2004;50(12):2331-7.
· Wallemacq PE. Therapeutic monitoring of immunosuppressant drugs. Where are we? Clin Chem.Lab Med. 2004;42(11):1204-11.
Anglicheau D, Legendre C, Thervet E. Pharmacogenetics in solid organ transplantation: present knowledge and future perspectives. Transplantation 2004;78(3):311-5.
Taylor PJ. Therapeutic drug monitoring of immunosuppressant drugs by high-performance liquid chromatography-mass spectrometry. Ther.Drug Monit. 2004;26(2):215-9.
Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem YF. Alterations of CYP3A4 and P-glycoprotein activity in vivo with time in renal graft recipients. Kidney Int. 2004;66(1):433-40.
Morris RG, Holt DW, Armstrong VW, Griesmacher A, Napoli KL, Shaw LM. Analytic aspects of cyclosporine monitoring, on behalf of the IFCC/IATDMCT joint working group. Therapeutic Drug Monitoring 2004;26:227-30.
Holt DW, Johnston A. Monitoring immunosuppressive drugs: Has it a future? Therapeutic Drug Monitoring 2004;26:244-7.
Butler JA, Peveler RC, Roderick P, Horne R, Mason JC. Measuring compliance with drug regimens after renal transplantation: comparison of self-report and clinician rating with electronic monitoring. Transplantation 2004;77(5):786-9.
Jorga A, Holt DW, Johnston A. Therapeutic drug monitoring of cyclosporine. Transplant.Proc. 2004;36(2 Suppl):396S-403S.
Citterio F. Evolution of the therapeutic drug monitoring of cyclosporine. Transplant.Proc. 2004;36(2 Suppl):420S-5S.
Brunet M, Millan O, Jimenez O, Campistol JM, Vidal E, Rojo I et al. New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations. Transplant.Proc. 2004;36(2 Suppl):437S-41S.
Perico N, Ruggenenti P, Gotti E, Gaspari F, Cattaneo D, Valente U et al. In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: Insights from the MY.S.S. Trial. Kidney Int. 2004;65(3):1084-90.
Bioanalytics and Forensic Toxicology
Read the PDF